View Author
tumor melphalan perfusion il -2 patient response treatment limb perfusion effect liver hepatic cancer histamine tissue study tumor necrosis factor toxicity hepatic perfusion necrosis concentration melanoma eggermont response rates factor metastase combination sarcoma huvec oncol netherland result group chapter survival vessel model growth grade volume disease animal permeability increase month tumor cells antitumor minute tumor tissue van tiel st uptake hypoxic hepatic perfusion leakage tumor response tumour hagen number colorectal medium portal vein hepatic artery method artery muscle agent catheter value -175 diameter macrophage brunstein activity figure portal staining hagen tl antitumor activity tumor vessels procedure tissue sarcomas vasculature
8 Most Recent Publications
|
Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases
(Article)
Etten, B. van Wilt, J.H.W. de Brunstein, F. Eggermont, A.M.M. Verhoef, C. |
2009-05-01
|
|
Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion
(Article)
Verhoef, C. Wilt, J.H.W. de Brunstein, F. Marinelli, A.W. Etten, B. van Vermaas, M. Guetens, G. Boeck, G. de Bruijn, E.A. de Eggermont, A.M.M. |
2008-05-01
|
|
Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion
(Article)
Brunstein, F. Hoving, S. Aan de Wiel-Ambagtsheer, G. Bruijn, E.A. de Guetens, G. Eggermont, A.M.M. Hagen, T.L.M. ten |
2007-04-01
|
|
Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases
(Article)
Brunstein, F. Eggermont, A.M.M. Wiel-Ambagtsheer, G.A. de Tiel, S.T. van Rens, J.A.P. Hagen, T.L.M.T. |
2007-02-01
|
|
Histamine’s vasoactive properties improving response rates in solid tumor treatment
(Doctoral Thesis)
Brunstein, F. |
2006-10-12
|
|
Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
(Article)
Etten, B. van Brunstein, F. Verhoef, C. IJken, M.G.A. van Marinelli, A.W. Sijp, J.R. van der Guetens, G. Boeck, G. de Bruijn, E.A. de Wilt, J.H.W. de Eggermont, A.M.M. |
2004-12-01
|
|
Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
(Article)
Brunstein, F. Hoving, S. Seynhaeve, A.L.B. Tiel, S.T. van Guetens, G. Bruijn, E.A. de Eggermont, A.M.M. Hagen, T.L.M. ten |
2004-11-03
|
|
One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases
(Article)
Grunhagen, D.J. Brunstein, F. Graveland, W.J. Geel, A.N. van Wilt, J.H.W. de Eggermont, A.M.M. |
2004-01-01
|
